|
|
|
| Long-term effect exploration of intravenous thrombolytic therapy with recombinant tissue-type plasminogen activator treating acute cerebral infarction |
| ZHONG Chuan-piao FANG Ling LAN Song |
| Department of Internal Medicine-Neurology,Maoming People′s Hospital of Guangdong Province,Maoming 525000,China |
|
|
|
|
Abstract ObjectiveTo explore the long-term effect of intravenous thrombolytic therapy with recombinant tissue-type plasminogen activator(r-tPA)treating acute cerebral infarction.MethodsFrom January 2015 to January 2017,100 patients with acute cerebral infarction admitted into our hospital were selected as research objects.Using a random number table method,they were divided into the two groups,and there were 50 cases in each group.All participants were provided with conventional therapy.On the basis of routine treatment,Aspirin Enteric-coated Tablets was added in the control group,while in the observation group,r-tPA was adopted.The clinical effect,prognosis,neurological deficit score,and Barthel index were compared between the two groups.ResultsAfter 3-month treatment,the clinical effect of the observation group was significantly better than that of the control group,and the prognosis in the observation group was better than that in the control group after 3-month treatment(P＜0.05).Before treatment,there was no statistical difference in the score of neurological deficits or Barthel index between the two groups (P＞0.05).After therapy,the score of neurological deficits in the two groups were both lower than those prior treatment(P＜0.05),and Barthel index were significantly higher than those before treatment(P＜0.05).The score of neurological impairment was lower and Barthel index was higher compared with those in the control group (P＜0.05).Conclusionr-tPA intravenous thrombolysis is effective in the treatment of acute cerebral infarction,which can facilitate the recovery of neurological function as well as daily living ability,and helps improve the long-term prognosis of patients.
|
|
|
|
|
|
| [1] |
毕敏，童绥君，张艺丹，等.r-tPA动脉溶栓治疗超时间窗急性脑梗死[J].中华急诊医学杂志，2013，22（4）：414-417.
|
| [2] |
王以翠，常焕显，孔令胜，等.重组组织型纤溶酶原激活剂动脉溶栓联合血管内治疗对早期脑梗死患者的疗效观察[J].中国急救医学，2016，36（7）：609-613.
|
| [3] |
张建，付慧霄，孙艳军，等.应用R-TPA溶栓治疗脑梗死病人溶栓后血管再闭塞的临床特点[J].中国老年学杂志，2016，36（8）：1868-1869.
|
| [4] |
孙巧松，温清艳，李广生，等.不同剂量阿托伐他汀对急性脑梗死静脉溶栓后患者预后及症状性出血的比较研究[J].中国医学创新，2017，14（18）：1-5.
|
| [5] |
周婷，徐小辉，王国珍，等.r-tPA静脉溶栓治疗急性脑梗死的疗效观察[J].现代实用医学，2012，24（1）：32-34.
|
| [6] |
娄志军.小剂量重组组织型纤溶酶原激活剂（r-tPA）治疗急性脑梗死的临床观察[J].医学理论与实践，2014，27（5）：599-600.
|
| [7] |
刘芳，史宗杰，张锦华，等.急性脑梗死患者r-tPA静脉溶栓后出血转化的风险预测研究[J].现代实用医学，2014，26（8）：968-969，985，封 3.
|
| [8] |
Eijiro O，Morio M，Kota W，et al.A case of spontaneous spinal epidural hematoma that mimicked acute cerebral ischemic stroke and was treated by a recombinant tissue-type plasminogen activator[J].Neurosurg Q，2012，22（2）：99-101.
|
| [9] |
张彤.急性脑梗死动脉溶栓血管再通后重组组织型纤溶酶原激活剂用法探讨[J].中国医药导报，2013，10（18）：82-85.
|
| [10] |
Osaki M，Miyashita F，Koga M，et al.Simple clinical predictors of stroke outcome based on National Institutes of Health Stroke Scale score during 1-h recombinant tissue-type plasminogen activator infusion[J].Eur J Neurol，2014，21（3）：411-418.
|
| [11] |
曾静，杨楠，彭慧渊，等.重组组织型纤溶酶原激活剂早期静脉溶栓治疗急性脑梗死的疗效观察[J].中外医学研究，2014，12（21）：23-24.
|
| [12] |
吴振宏，钟才，乔振虎，等.CTA下阿替普酶在急性脑梗死溶栓中应用效果观察及对日后生活质量的影响[J].中国实用神经疾病杂志，2014，17（10）：85-87.
|
| [13] |
闫舫.静脉溶栓治疗急性脑梗死31例临床效果分析[J].中外医疗，2013，32（26）：93-94.
|
| [14] |
李君，屈泽暖，王献勇，等.r-tPA静脉溶栓治疗急性脑梗死的临床效果观察[J].中国临床实用医学，2016，10（1）：80-81.
|
| [15] |
Whiteley WN，Thompson D，Murray G，et al.Targeting recombinant tissue-type plasminogen activator in acute ischemic stroke based on risk of intracranial hemorrhage or poor functional outcome：an analysis of the third international stroke trial[J].Stroke，2014，45（4）：1000-1006.
|
|
|
|
